Bliss GVS Pharma Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Bliss GVS Pharma (NSE: BLISSGVS) Q4 FY26 results are scheduled for May 12, 2026. Trading at Rs 148 as of April 2026 — down -32% from its 52-week high of Rs 228 — the stock has been on investors’ watchlist ahead of what could be a pivotal quarterly result. This article covers the confirmed results date, analyst consensus estimates, five performance factors, five risks, analyst ratings, and share price outlook for Bliss GVS Pharma.

Q4 (January-March 2026) is the year’s final quarter, bringing full-year FY26 results, management’s FY27 guidance, and the final dividend recommendation — all from a single board meeting on May 12, 2026.

Get free investment predictions from SEBI-registered analysts on Univest.

Bliss GVS Pharma Q4 Results 2026 Date

Bliss GVS Pharma Q4 FY26 results date is May 12, 2026.

Why Q4 FY26 Matters

Q4 FY26 is the final quarter of FY2025-26. Bliss GVS Pharma’s board on May 12, 2026 will approve the full-year FY26 results, consider a final dividend recommendation, and provide the first formal commentary on FY27 business outlook — making this the single most important results event of the year.

Bliss GVS Pharma Q4 FY26 Earnings Estimates

Access premium research on Univest.

Screen Bliss GVS Pharma live on the Univest Screener. Download the Univest iOS App or Univest Android App for real-time Q4 result alerts.

5 Key Factors Driving Bliss GVS Pharma Q4 FY26 Performance

1. Emerging Market Pharma Export

Bliss GVS exports pharma products to Africa, CIS, and Southeast Asia markets where branded generics command premium pricing.

2. Suppository and Dosage Form Expertise

Bliss GVS has technical differentiation in suppository and other specialty dosage forms.

3. Regulatory Dossier Expansion

New product registrations in target export markets expand addressable revenue.

4. Currency Management

USD export revenue management and hedging.

5. African Healthcare Market Growth

Growing healthcare access in Sub-Saharan Africa drives pharmaceutical demand.

5 Risks to Watch in Bliss GVS Pharma Q4 FY26

Risk 1: Pharma Exports Sector Risk

Sector headwinds including input cost pressure, demand cyclicality, and competition could impact Q4 performance.

Risk 2: Revenue Concentration

Customer or geographic concentration creates variance risk.

Risk 3: Regulatory Environment

Policy and regulatory changes in the sector can create compliance or revenue risks.

Risk 4: Working Capital Management

Efficient working capital management determines free cash flow quality in Q4.

Risk 5: Macroeconomic Sensitivity

Global and domestic macroeconomic conditions affect end-market demand.

Bliss GVS Pharma Share Price and Analyst Ratings

Conclusion

Bliss GVS Pharma Q4 FY26 results on May 12, 2026 will reflect Pharma Exports sector performance in the January-March 2026 quarter. Revenue above Rs 285 Cr with EBITDA 12% would constitute a beat. The +12% export revenue trajectory and management FY27 guidance are the primary catalysts for re-rating. At Rs 148 — down -32% from its 52-week high of Rs 228 — the stock offers a more reasonable entry point than earlier in the year.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

Q: When is Bliss GVS Pharma Q4 results 2026 date?

Bliss GVS Pharma Q4 FY26 results date is May 12, 2026. The board of directors will approve the quarter and full-year FY26 results and consider recommending a final dividend for FY26 shareholders.

Q: What is Bliss GVS Pharma Q4 FY26 revenue estimate?

Analyst consensus estimate for Bliss GVS Pharma Q4 FY26 revenue is Rs 285 Cr. Q3 FY26 actual revenue was Rs 255 Cr. Actual Q4 results may differ based on operating conditions.

Q: What is Bliss GVS Pharma Q4 FY26 PAT estimate?

Analyst consensus estimate for Bliss GVS Pharma Q4 FY26 net profit (PAT) is Rs 22 Cr. Q3 FY26 actual PAT was Rs 18 Cr.

Q: Will Bliss GVS Pharma declare a dividend in Q4 FY26?

Bliss GVS Pharma is expected to declare Rs 0.50 for FY26, subject to board approval on May 12, 2026 and shareholder approval at the AGM.

Q: What is Bliss GVS Pharma’s current share price?

Bliss GVS Pharma is trading at Rs 148 as of April 2026, with a 52-week range of Rs 125 to Rs 228. The 1-year return is -32%.

Q: What were Bliss GVS Pharma Q3 FY26 results?

In Q3 FY26, Bliss GVS Pharma reported revenue of Rs 255 Cr and PAT of Rs 18 Cr. Q4 FY26 on May 12, 2026 provides the year-end comparison.

Q: When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Infosys is scheduled for April 23, 2026. Both are covered on Univest Blogs.

Q: Is Bliss GVS Pharma a good investment ahead of Q4 results?

This article does not constitute investment advice. Bliss GVS Pharma trades at Rs 148 — down -32% from its peak. Consult a SEBI-registered advisor before investing.

Recent Article

Balkrishna Industries Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Balkrishna Paper Mills Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

BALAXI PHARMACEUTICALS Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Balaji Telefilms Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Balaji Amines Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook